3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
27
Prostatic Neoplasms
12
Leukemia
12
Lymphoma
7
Burkitt Lymphoma
7
Leukemia, Biphenotypic, Acute
6
Lymphoma, Large B-Cell, Diffuse
5
Recurrence
4
Lymphoma, Non-Hodgkin
4
Pituitary Neoplasms
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, B-Cell
3
Leukemia, Myeloid, Acute
3
Hodgkin Disease
3
Rhabdoid Tumor
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Polycystic Ovary Syndrome
2
Obesity
2
Neoplasms
2
Multiple Myeloma
2
Lymphoma, T-Cell
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Follicular
2
Hematologic Neoplasms
2
Radiodermatitis
1
Pyloric Stenosis, Hypertrophic
1
Plasmablastic Lymphoma
1
Pituitary Diseases
1
Pinealoma
1
Interventions
Fulvestrant
2
ruxolitinib
1
dexpanthenol
1
ceterizine hydrochloride
1
capivasertib
1
benralizumab
1
Triamcinolone Acetonide
1
Tetracycline
1
Provitamins
1
Prednisone
1
Minocycline
1
Loperamide
1
Interviews as Topic
1
Hydrocortisone
1
HIV Testing
1
Gels
1
Fibroblast Growth Factor 7
1
Erlotinib Hydrochloride
1
Doxycycline
1
Dapsone
1
Clindamycin
1
Cetuximab
1
Anti-Bacterial Agents
1
Alpelisib
1
Acitretin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Exanthema
×
Hydrocortisone
×
Clear all
NCT00473083
2017-04-04
LUTRAERL
British Columbia Cancer Agency
Phase 2
Completed
150 enrolled
13 charts